Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of MEDI-563 in adults with uncontrolled asthma
2010-020126-17Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma and eosinophilic asthma (EA) comparing MEDI-563 with Placebo (2 arms). Primary endpoint: Annual asthma exacerbation rate. Started Apr 2011; status: completed.
02
Drugs
benralizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2010-020126-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020126-17.